Livongo Health said today it will integrate continuous glucose data from Abbott‘s (NYSE:ABT) FreeStyle Libre Pro system into its Livongo for Diabetes system, touting it as the first such system to integrate data from Abbott’s FreeStyle Libre Pro. With the integration, users of the FreeStyle Libre Pro will be able to see a visual snapshot of […]
MicroPort’s drug-eluting stent performs well in European study
MicroPort Scientific’s Firehawk rapamycin target eluting coronary stent performed comparably to Abbott’s Xience stent family in a study just published in The Lancet. The TARGET AC multi-center, randomized controlled trial enrolled 1,653 patients at 21 clinical study sites in Europe. Firehawk met the trial’s non-inferiority primary endpoint of target lesion failure rate at 12 months of 6.1% versus […]
Abbott wins FDA nod for 14-day FreeStyle Libre glucose sensor
Abbott (NYSE:ABT) said today that the FDA approved its 14-day FreeStyle Libre flash glucose monitor, making the device the longest lasting self-applied glucose sensor on the market. The company’s FreeStyle Libre system, initially approved to last 10 days, is designed to eliminate the need for fingersticks. Users can test their blood sugar with the continuous glucose […]
Abbott CEO aims for more than one million Libre users by 2019
Topping estimates on Wall Street, Abbott (NYSE:ABT) posted a hefty beat yesterday with its second-quarter financial results. Driving the company’s growth was, in part, its diabetes business unit – sales jumped nearly 40% compared to Q2 in 2017 thanks largely to its sensor-based glucose monitoring system, Freestyle Libre. “Libre offers a true mass-market opportunity with its […]
Sales for Abbott’s diabetes business jump 40% in Q2
Abbott (NYSE:ABT) shares were up today after the healthcare company posted second-quarter financial results that topped estimates on Wall Street. For the three months ended June 30, Abbott posted profits of $733 million, or 41¢ per share, on sales of $7.77 billion. The company saw its quarterly profits grow 159% on sales growth of 17% compared […]
FDA approves Abbott’s latest drug-eluting stent
Abbott (NYSE:ABT) said today that it won FDA approval for its Xience Sierra everolimus-eluting coronary stent. The company’s device features a thin profile, improved flexibility and longer lengths than previous stents. The device and delivery system were designed to help clinicians tackle complex cases, like those involving multiple or totally blocked vessels, according to Abbott. “We […]
For this Abbott executive, solving problems isn’t enough: ‘We need to add value’
As payers and providers across healthcare shift their focus to value-based care, leaders in the medical device industry are racing to keep up. Michael Pederson, SVP of cardiac arrhythmias and heart failure at Abbott, told MassDevice.com why simply solving problems with new technology isn’t enough anymore. What was your path like from electrical engineering to […]
Abbott’s Xience Sierra drug-eluting coronary stent wins reimbursement in Japan
Abbott (NYSE:ABT) said today that it won national reimbursement in Japan for its everolimus-eluting stent, Xience Sierra, which is designed to treat patients with coronary artery disease. The company’s latest drug-eluting device features a thinner profile, increased flexibility and longer lengths than previous stents, according to Abbott. The healthcare firm said it developed Xience Sierra to […]
Medtech stories we missed this week: April 27, 2018
From DuPuy Synthes’s spinal implant launch to Lumendi’s FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. DePuy Synthes launches spinal implants DePuy Synthes announced in an April 26 press release that it has launched its Proti 360º integrated titanium family of interbody devices that are designed to […]
Abbott pulls Xience Alpine drug-eluting stent from Indian market
Abbott (NYSE:ABT) reportedly stopped selling its Xience Alpine drug-eluting coronary stent in India this week in response to price caps set by the National Pharmaceutical Pricing Authority. A spokesperson for the healthcare firm said in a statement that Abbott “fulfilled all the requirements to discontinue selling its Xience Alpine drug-eluting stent in India as of April […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 7
- Next Page »
